Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of FE 999303 (Testosterone Gel) Extension in Hypogonadal Males
NCT01703741Phase 3Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Dec 2012
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of Testosterone TEPI patch in male hypogonadism, sponsored by Ferring Pharmaceuticals. Primary endpoint: Percentage of Subjects With a Serum Total Testosterone Level - Maximum Observed Concentration (Cmax) of 1500-1799, 1800-2499, or Above 2500 ng/dL. Started Dec 2012; status: completed.
02
Drugs
Testosterone TEPI patch
03
Conditions
male hypogonadism
Beyond the preview
Go deeper on NCT01703741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01703741.